Literature DB >> 3701533

Lung defense against infection.

P G Quie.   

Abstract

The human lung has an exquisitely effective and complex defense against infections. Mucus prevents attachment of bacteria to the epithelium, and those bacteria that cannot cross the mucus are cleared by exhalation or by the mucus-ciliary escalator. Alveolar macrophages dispatch microbes that reach the peripheral barriers of the lung. The pulmonary phagocytic system immobilizes, kills, and walls off invading bacteria. The phagocytic system, developed in bone marrow, includes alveolar macrophages, granulocytes, and monocytes. The phagocytic system is amplified by humoral factors, including inflammatory mediators, acute-phase reactants, and opsonins that allow rapid engulfment and killing of microbes. Highly mobile polymorphonuclear granulocytes reinforce the macrophages when invading organisms reach tissue. Sterility of the lower respiratory tract in the normal host is evidence that the defense systems of the lung are highly effective and potently bactericidal. The oxidative and nonoxidative microbicidal mechanisms of alveolar macrophages and granulocytes are lethal for most ordinary microbes. However, certain pathogens have means of preventing phagocytosis, and obligate intracellular species have evolved mechanisms of intracellular survival. Successful biologic détente between microbe and host is the usual situation in the normal human lung, but the relationship is unfortunately short-lived in patients with cystic fibrosis. Mucus is not an adequate barrier in these patients. Bacterial pathogens colonize respiratory tissue and, as a consequence, compromise lung function. Better understanding of local defenses in normal human lungs and of the defects in lung defenses in patients with cystic fibrosis should lead to methods that will provide these patients with successful defense against invading microbes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3701533     DOI: 10.1016/s0022-3476(86)80750-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Immunoglobulin and anti-Escherichia coli antibody in lower respiratory tract secretions from infants weighing less than 1500 g at birth.

Authors:  F H Sennhauser; A Balloch; M J Shelton; L W Doyle; V Y Yu; D M Roberton
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

2.  Immunoglobulin profile of tracheal aspirate fluid in intubated children.

Authors:  K Forsyth; L Koh; A Lawrence; J Bradley
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

3.  An ELISA to detect antipseudomonal IgA antibodies in sera of patients with cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

Review 4.  Dysbiosis: from fiction to function.

Authors:  Connor R Tiffany; Andreas J Bäumler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-11       Impact factor: 4.052

Review 5.  IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.

Authors:  Aymn Talat Abbas; Sherif Aly El-Kafrawy; Sayed Sartaj Sohrab; Esam Ibraheem Ahmed Azhar
Journal:  Hum Vaccin Immunother       Date:  2018-09-19       Impact factor: 3.452

6.  Flow Cytometric Analysis of Leukocyte Populations in the Lung Tissue of Dromedary Camels.

Authors:  Jamal Hussen; Turke Shawaf; Naser Abdallah Al Humam; Sameer M Alhojaily; Mohammed Ali Al-Sukruwah; Faisal Almathen; Francesco Grandoni
Journal:  Vet Sci       Date:  2022-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.